Yuna Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuna Hwang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hyukjin Lee
College of Pharmacy, Seoul National University, Seoul, Republic of Korea
3 shared publications - Hyuk-Jin Cha
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea
2 shared publications Beom-Jin Jeon
Laboratory of Theriogenology and Biotechnology, Department of Veterinary Clinical Science, College of Veterinary Medicine and the Research Institute of Veterinary Science, Seoul National University, Seoul, Republic of Korea
1 shared publicationDong-Hyeok Kwon
Laboratory of Theriogenology and Biotechnology, Department of Veterinary Clinical Science, College of Veterinary Medicine and the Research Institute of Veterinary Science, Seoul National University, Seoul, Republic of Korea
1 shared publication- Dong-Woo Kim
College of Pharmacy, Seoul National University, Seoul, Republic of Korea
1 shared publication - Eun Hye Jeong
Surginex Co., Ltd., Omnibus Park, Seoul 06591, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (10) , 3370-3381
Patient-derived teratomas as a humanized platform for dystrophin restoration by ex vivo cell therapy and in vivo base editing
Cell and gene therapies hold great promise for treating monogenic disorders, yet their preclinical evaluation remains limited by the lack of scalable, human-specific models. Here we establish a patient-derived teratoma xenograft platform as a proof-of-concept system to evaluate ex vivo and in vivo therapeutic strategies for Duchenne muscular dystrophy (DMD). Teratomas generated from DMD patient-derived induced pluripotent stem cells contained mesodermal derivatives, including skeletal muscle-like tissue, enabling assessment of dystrophin restoration after therapeutic intervention. For ex vivo cell therapy, myogenic progenitors derived from adenine base editor-corrected induced pluripotent stem cells were transplanted into DMD teratomas, resulting in partial restoration of shorter dystrophin isoforms but not reproducible recovery of full-length Dp427m. For in vivo gene editing, local delivery of adenine base editor mRNA encapsulated in lipid nanoparticles induced dose-dependent editing and restoration of shorter dystrophin isoforms, including Dp71. Full-length, muscle-specific Dp427m was detected only in a subset of sequentially matured secondary teratomas with enriched muscle differentiation, indicating that myogenic maturation is a critical determinant of this therapeutic readout. Together, these findings support patient-derived DMD teratomas as an exploratory humanized platform for evaluating patient-specific gene correction and dystrophin isoform restoration, while highlighting the need for further optimization to reproducibly model full-length Dp427m recovery.
- 1 October 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (10) , 3370-3381
Open AccessPatient-derived teratomas as a humanized platform for dystrophin restoration by ex vivo cell therapy and in vivo base editing
Cell and gene therapies hold great promise for treating monogenic disorders, yet their preclinical evaluation remains limited by the lack of scalable, human-specific models. Here we establish a patient-derived teratoma xenograft platform as a proof-of-concept system to evaluate ex vivo and in vivo therapeutic strategies for Duchenne muscular dystrophy (DMD). Teratomas generated from DMD patient-derived induced pluripotent stem cells contained mesodermal derivatives, including skeletal muscle-like tissue, enabling assessment of dystrophin restoration after therapeutic intervention. For ex vivo cell therapy, myogenic progenitors derived from adenine base editor-corrected induced pluripotent stem cells were transplanted into DMD teratomas, resulting in partial restoration of shorter dystrophin isoforms but not reproducible recovery of full-length Dp427m. For in vivo gene editing, local delivery of adenine base editor mRNA encapsulated in lipid nanoparticles induced dose-dependent editing and restoration of shorter dystrophin isoforms, including Dp71. Full-length, muscle-specific Dp427m was detected only in a subset of sequentially matured secondary teratomas with enriched muscle differentiation, indicating that myogenic maturation is a critical determinant of this therapeutic readout. Together, these findings support patient-derived DMD teratomas as an exploratory humanized platform for evaluating patient-specific gene correction and dystrophin isoform restoration, while highlighting the need for further optimization to reproducibly model full-length Dp427m recovery.
- Open Access
- 31 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Mutation-agnostic base editing of the progerin farnesylation site rescues Hutchinson-Gilford progeria syndrome phenotypes in neuromuscular organoids
Hutchinson Gilford progeria syndrome (HGPS) is a fatal premature aging disorder caused by pathogenic farnesylated lamin A variants that disrupt nuclear architecture and DNA repair. Current therapies, including farnesyltransferase inhibitors, provide only modest survival benefits and lack molecular specificity, while mutation-specific genome-editing strategies cannot address atypical laminopathies. Here, we develop Farnesylation Amino acid Targeted Editing (FATE), a mutation-agnostic base-editing platform that selectively disrupts the LMNA farnesylation motif without affecting other farnesylated proteins. Using isogenic human pluripotent stem cell derived neuromuscular organoids (NMOs), we reveal muscle-specific progerin accumulation that sequesters 53BP1 and abolishes DNA damage foci formation. FATE eliminates perinuclear progerin, restores 53BP1 mobility, reconstitutes DNA repair foci, and normalizes heterochromatin architecture. Importantly, transient delivery of FATE mRNA conjugated with lipid nanoparticles to HGPS NMOs achieves efficient base editing and phenotypic rescue. These findings establish FATE as a mutation-independent therapeutic strategy targeting a fundamental pathogenic mechanism in HGPS and provide a proof-of-concept for RNA-based in situ genome editing in progeroid disease.
- 31 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMutation-agnostic base editing of the progerin farnesylation site rescues Hutchinson-Gilford progeria syndrome phenotypes in neuromuscular organoids
Hutchinson Gilford progeria syndrome (HGPS) is a fatal premature aging disorder caused by pathogenic farnesylated lamin A variants that disrupt nuclear architecture and DNA repair. Current therapies, including farnesyltransferase inhibitors, provide only modest survival benefits and lack molecular specificity, while mutation-specific genome-editing strategies cannot address atypical laminopathies. Here, we develop Farnesylation Amino acid Targeted Editing (FATE), a mutation-agnostic base-editing platform that selectively disrupts the LMNA farnesylation motif without affecting other farnesylated proteins. Using isogenic human pluripotent stem cell derived neuromuscular organoids (NMOs), we reveal muscle-specific progerin accumulation that sequesters 53BP1 and abolishes DNA damage foci formation. FATE eliminates perinuclear progerin, restores 53BP1 mobility, reconstitutes DNA repair foci, and normalizes heterochromatin architecture. Importantly, transient delivery of FATE mRNA conjugated with lipid nanoparticles to HGPS NMOs achieves efficient base editing and phenotypic rescue. These findings establish FATE as a mutation-independent therapeutic strategy targeting a fundamental pathogenic mechanism in HGPS and provide a proof-of-concept for RNA-based in situ genome editing in progeroid disease.
- Open Access
A Rapidly Excretable, ROS-Scavenging Ionizable Lipid Decouples mRNA Delivery Potency from Toxicity
The broader clinical application of mRNA therapeutics remains constrained by dose-limiting toxicities, vector-associated immunogenicity, and prolonged tissue retention of lipid nanoparticles (LNPs) in vivo. Here, we report a class of ionizable lipids incorporating a sulfur-bearing hexyl 2-hydroxyethyl sulfide (HHES) motif that decouples mRNA delivery potency from these safety liabilities through dual functionality: the sulfur moiety acts as an intrinsic reactive oxygen species scavenger to suppress oxidative stress, while undergoing oxidative conversion into hydrophilic metabolites to promote rapid systemic clearance. HHES-based LNPs demonstrated a 3.3-fold shorter hepatic half-life and 29-fold lower total hepatic exposure than MC3, while maintaining robust protein expression including functional monoclonal antibody production in vivo. Repeated dosing in non-human primates confirmed negligible systemic, hepatic, or hematological toxicity. Leveraging this safety profile, subretinal HHES LNP delivery achieved up to 57% genome editing efficiency in retinal pigment epithelium, suppressing choroidal neovascularization by ~65% in a wet age-related macular degeneration model without structural damage or microglial activation. This dual-function design provides a generalizable framework for safe, transient, non-accumulative mRNA nanomedicines.
Open AccessA Rapidly Excretable, ROS-Scavenging Ionizable Lipid Decouples mRNA Delivery Potency from Toxicity
The broader clinical application of mRNA therapeutics remains constrained by dose-limiting toxicities, vector-associated immunogenicity, and prolonged tissue retention of lipid nanoparticles (LNPs) in vivo. Here, we report a class of ionizable lipids incorporating a sulfur-bearing hexyl 2-hydroxyethyl sulfide (HHES) motif that decouples mRNA delivery potency from these safety liabilities through dual functionality: the sulfur moiety acts as an intrinsic reactive oxygen species scavenger to suppress oxidative stress, while undergoing oxidative conversion into hydrophilic metabolites to promote rapid systemic clearance. HHES-based LNPs demonstrated a 3.3-fold shorter hepatic half-life and 29-fold lower total hepatic exposure than MC3, while maintaining robust protein expression including functional monoclonal antibody production in vivo. Repeated dosing in non-human primates confirmed negligible systemic, hepatic, or hematological toxicity. Leveraging this safety profile, subretinal HHES LNP delivery achieved up to 57% genome editing efficiency in retinal pigment epithelium, suppressing choroidal neovascularization by ~65% in a wet age-related macular degeneration model without structural damage or microglial activation. This dual-function design provides a generalizable framework for safe, transient, non-accumulative mRNA nanomedicines.